Rab32 puts itaconate where it's needed: Myeloid cells can restrict the replication of intracellular bacterial pathogens such as Salmonella using a Rab family guanosine triphosphatase called Rab32. However, the underlying mechanisms remain unclear. Chen et al. report that Rab32 and its exchange factor, BLOC3, interact with aconitate decarboxylase 1 (IRG1). This complex enables the direct delivery of IRG1's antimicrobial product, itaconate, from the mitochondria to Salmonella -containing vacuoles. Itaconate concentrations in vacuoles correlated with bacterial survival, highlighting the biological relevance of this metabolite during infections. Similar findings in Escherichia coli –infected cells suggest that this is a more general phenomenon in which mitochondria and the Rab32 pathway play a critical role in antibacterial host defense. Science , this issue p. 450
Itaconate accumulates in macrophages upon bacterial infection, and manifests antibacterial activity. Convincing evidence substantiates that itaconate is transported across the plasma membrane and vacuolar membrane, but the molecular bases underlying bidirectional transport of itaconate across membranes and its effects on intracellular bacterial replication are less known. Here, we identify MCT1 and MCT4 as bidirectional transporters of itaconate. In addition to modulating itaconate concentration as transporters at the plasma membrane, MCT1 and MCT4 function as itaconate transporters at Salmonella -containing vacuole (SCV). Upon Salmonella infection, MCT1 and MCT4 transport itaconate into SCV facilitated by RAB32. Itaconate is also secreted out of cells through MCT1 and MCT4 as the infection persists. The suppression of MCT1 and MCT4-dependent itaconate secretion increases the overall concentration of itaconate and the proportion of itaconate-targeted Salmonella intracellularly, consequently inhibiting Salmonella replication. Our study thus offers valuable insights into itaconate transport during bacterial infection and provides proof of principle for the development of itaconate-dependent therapeutic strategies.